Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58862 | 0.79 | MEN1 (0.36) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL7701111 | 0.79 | ALDH1A1 (0.32) | GABRA1GABRB2ALDH1A1POLB | |
| SCHEMBL27806339 | 0.77 | LOXL2 (0.37) | ALDH1A1TSHRHPGD | |
| SCHEMBL16957068 | 0.77 | ALDH1A1 (0.39) | ALDH1A1TSHRL3MBTL1HPGD | |
| SCHEMBL29015148 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHRHPGD | |
| SCHEMBL1173930 | 0.75 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1TSHRPOLB | |
| SCHEMBL10746013 | 0.75 | TAAR1 (0.37) | MEN1KMT2AALDH1A1TSHRHPGD | |
| SCHEMBL2256046 | 0.74 | ALDH1A1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL27946150 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPTL3MBTL1MAPK1 | |
| SCHEMBL831218 | 0.73 | TDP1 (0.37) | MEN1KMT2AALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4293306-A | Process for the dyeing and printing of hydrophobic synthetic organic fiber materials with water-insoluble azo dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-10-06 | — | — | US | claimed |
| CN-101006052-B | Pyrrole derivatives as pharmaceutical agents | EXELIXIS INC | 2013-11-06 | — | — | CN | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-7704924-B2 | Library of compounds comprising pyrrolobenzodiazepine moieties | SPIROGEN LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| CN-100369905-C | Antibiotic & antifouling oxathiazine and its oxide | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1575486-A4 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1575486-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005044308-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | GILEAD SCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004096237-A2 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6608192-B1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-08-19 | — | — | US | disclosed |
| CN-1322720-A | Antibiotic & antifouling oxathiazine and its oxide | JANSSEN PHARMACEUTICA NV (BE) | 2001-11-21 | — | — | CN | disclosed |
| US-4293306-A | Process for the dyeing and printing of hydrophobic synthetic organic fiber materials with water-insoluble azo dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | GABRA1 1862/4885GABRB2 1488/4885MEN1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.